Skip to content
10-K

Annual Report

VIRPAX PHARMACEUTICALS, INC.

0001731122-25-000316

← back to feed
Filed
Mar 3, 2025 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2024 · Feb 26, 2025 26.56M sh
Shares Diluted FY 2024 · Dec 31, 2024 4.25M sh
Shares Diluted FY 2024 · Dec 31, 2023 1.17M sh
Operating Cash Flow FY 2024 · Dec 31, 2024 −$16.71M
Operating Cash Flow FY 2024 · Dec 31, 2023 −$9.85M
Stockholders Equity FY 2024 · Dec 31, 2024 −$913.76K
Stockholders Equity FY 2024 · Dec 31, 2023 $1.93M
Stockholders Equity FY 2024 · Dec 31, 2022 $16.58M
Current Liabilities FY 2024 · Dec 31, 2024 $2.47M
Current Liabilities FY 2024 · Dec 31, 2023 $7.69M
Total Liabilities FY 2024 · Dec 31, 2024 $2.47M
Total Liabilities FY 2024 · Dec 31, 2023 $7.69M
Current Assets FY 2024 · Dec 31, 2024 $1.56M
Current Assets FY 2024 · Dec 31, 2023 $9.63M
Total Assets FY 2024 · Dec 31, 2024 $1.56M
Total Assets FY 2024 · Dec 31, 2023 $9.63M
Eps Diluted FY 2024 · Dec 31, 2024 −$2.84
Eps Diluted FY 2024 · Dec 31, 2023 −$12.97
Eps Basic FY 2024 · Dec 31, 2024 −$2.84
Eps Basic FY 2024 · Dec 31, 2023 −$12.97
Sga Expense FY 2024 · Dec 31, 2024 $6.26M
Sga Expense FY 2024 · Dec 31, 2023 $10.57M
Rd Expense FY 2024 · Dec 31, 2024 $5.82M
Rd Expense FY 2024 · Dec 31, 2023 $5.12M
Net Income FY 2024 · Dec 31, 2024 −$12.07M
Net Income FY 2024 · Dec 31, 2023 −$15.19M
Operating Income FY 2024 · Dec 31, 2024 −$12.08M
Operating Income FY 2024 · Dec 31, 2023 −$15.69M